- Home
- CPIX
as 11-15-2024 9:42am EST
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE, |
| Market Cap: | 17.2M | IPO Year: | 2009 |
| Target Price: | N/A | AVG Volume (30 days): | 80.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.07 - $2.36 | Next Earning Date: | 11-07-2024 |
| Revenue: | $36,785,442 | Revenue Growth: | -6.45% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cumberland Pharmaceuticals Inc. (CPIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Krogulski Kenneth | CPIX | Director | Oct 1 '24 | Buy | $1.28 | 7,107 | $9,106.23 | 256,800 |
Latest Cumberland Pharmaceuticals Inc. News
CPIX Breaking Stock News: Dive into CPIX Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023)
GuruFocus.com
7 days ago
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ...
Associated Press Finance
8 days ago
Cumberland: Q3 Earnings Snapshot
PR Newswire
8 days ago
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
PR Newswire
9 days ago
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
PR Newswire
10 days ago
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
PR Newswire
15 days ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
Associated Press Finance
3 months ago
Cumberland: Q2 Earnings Snapshot
Compare CPIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPIX Cumberland Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.